These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 17530729)
1. Synthesis and evaluation of 3-phenylpyrazolo[3,4-d]pyrimidine-peptide conjugates as Src kinase inhibitors. Kumar A; Wang Y; Lin X; Sun G; Parang K ChemMedChem; 2007 Sep; 2(9):1346-60. PubMed ID: 17530729 [TBL] [Abstract][Full Text] [Related]
2. Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase. Huang H; Ma J; Shi J; Meng L; Jiang H; Ding J; Liu H Bioorg Med Chem; 2010 Jul; 18(13):4615-24. PubMed ID: 20570525 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and pp60c-Src tyrosine kinase inhibitory activities of novel indole-3-imine and amine derivatives substituted at N1 and C5. Kiliç Z; Isgör YG; Olgen S Arch Pharm (Weinheim); 2009 Jun; 342(6):333-43. PubMed ID: 19475593 [TBL] [Abstract][Full Text] [Related]
4. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck). Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643 [TBL] [Abstract][Full Text] [Related]
6. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Nam NH; Lee S; Ye G; Sun G; Parang K Bioorg Med Chem; 2004 Nov; 12(22):5753-66. PubMed ID: 15498652 [TBL] [Abstract][Full Text] [Related]
7. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816 [TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. Alfaro-Lopez J; Yuan W; Phan BC; Kamath J; Lou Q; Lam KS; Hruby VJ J Med Chem; 1998 Jun; 41(13):2252-60. PubMed ID: 9632358 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and activity of novel 5-substituted pyrrolo[2,3-d]pyrimidine analogues as pp60(c-Src) tyrosine kinase inhibitors. Olgen S; Isgör YG; Coban T Arch Pharm (Weinheim); 2008 Feb; 341(2):113-20. PubMed ID: 18214841 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Kim DK; Lim JH; Lee JA; Dewang PM Bioorg Med Chem Lett; 2008 Jul; 18(14):4006-10. PubMed ID: 18571921 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors. Dincer S; Cetin KT; Onay-Besikci A; Ölgen S J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720 [TBL] [Abstract][Full Text] [Related]
12. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain. Nam NH; Pitts RL; Sun G; Sardari S; Tiemo A; Xie M; Yan B; Parang K Bioorg Med Chem; 2004 Feb; 12(4):779-87. PubMed ID: 14759738 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of new indole and bromoindole derivatives as pp60(c-Src) tyrosine kinase inhibitors. Kiliç Z; Işgör YG; Olgen S Chem Biol Drug Des; 2009 Oct; 74(4):397-404. PubMed ID: 19691468 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors. Marchetti F; Cano C; Curtin NJ; Golding BT; Griffin RJ; Haggerty K; Newell DR; Parsons RJ; Payne SL; Wang LZ; Hardcastle IR Org Biomol Chem; 2010 May; 8(10):2397-407. PubMed ID: 20448898 [TBL] [Abstract][Full Text] [Related]
15. Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases. Enkvist E; Kriisa M; Roben M; Kadak G; Raidaru G; Uri A Bioorg Med Chem Lett; 2009 Nov; 19(21):6098-101. PubMed ID: 19800227 [TBL] [Abstract][Full Text] [Related]
17. Click chemistry inspired one-pot synthesis of 1,4-disubstituted 1,2,3-triazoles and their Src kinase inhibitory activity. Kumar D; Reddy VB; Kumar A; Mandal D; Tiwari R; Parang K Bioorg Med Chem Lett; 2011 Jan; 21(1):449-52. PubMed ID: 21084189 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2,2,2-trifluoroethoxysulfonates. Wong C; Griffin RJ; Hardcastle IR; Northen JS; Wang LZ; Golding BT Org Biomol Chem; 2010 May; 8(10):2457-64. PubMed ID: 20448906 [TBL] [Abstract][Full Text] [Related]
19. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships. Horiuchi T; Chiba J; Uoto K; Soga T Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of highly substituted dibenzo[b,f]azocines and their evaluation as protein kinase inhibitors. Arnold LA; Kiplin Guy R Bioorg Med Chem Lett; 2006 Oct; 16(20):5360-3. PubMed ID: 16890431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]